Recon: Mylan Signs Licensing Deal on Humira with AbbVie

• South Dakota judge blocks drug price cap measure from ballot (AP News) (STAT)
• Pharma fuels Johnson & Johnson's earnings beat, consumer lags (CNBC) (Reuters) (WSJ)
• Mylan signs U.S. license deal on Humira with AbbVie (Reuters) (The Center for Biosimilars)
• Roche hands over another batch of positive PhIII data on its new flu drug, looking for an early-winter launch (Endpoints) (Reuters) (PMLiVE) (Fierce) (pharmaphorum)
• Staggering Prices Slow Insurers’ Coverage Of CAR-T Cancer Therapy (KHN) (NPR) (STAT-$)
• Industry responds to Trump's drug plan with more finger-pointing (Axios) (STAT-$) (GEN)
• Takeda, Celgene Invest $6 Million in Presage Biosciences Cancer Testing Technology (BioSpace)
• Invokana renal trial stopped early for efficacy (BioPharma Dive) (Endpoints) (PMLiVE)
• Nimbus veterans launch allosteric drugmaker HotSpot Therapeutics with $45M series A (Fierce) (Boston Business Journal-$) (BioSpace) (C&EN) (Endpoints)
• Bristol-Myers Squibb to lay off 149 as Wallingford, Connecticut, site nears closure (Fierce)

• Ieon-nanodrugs announces collaboration with Takeda (BioSpectrum) (The Pharma Letter)
• Ascentage third round garners $150M for apoptosis cancer drugs (Fierce) (BioSpace)
• Roivant Launches New China-Based Startup Sinovant Sciences (BioSpace) (Fierce)
• Pfizer halts production at Hospira site after Form 483 (In-PharmaTechnologist) (STAT-$) (Fierce)
• Australia warned UK about ‘dangerous’ Graseby syringe pumps 15 years ago (The Times)
• WHO calls for accelerating efforts to reach nearly 5 million unvaccinated children (Press Trust of India) (Pharmabiz)
• Aurobindo’s Apotex deal marks ‘Enter Europe’ plan of Indian pharma companies (The Hindu Business Line)

• Microsoft, Walmart ink AI, cloud pact to take on Amazon (Healthcare IT News)
• Tammy Baldwin wants "permanent" price cuts for Pfizer's drug (Axios)
• Ogilvy CommonHealth’s North America CEO snags new chief creative officer (Fierce)
• Purdue defends against opioid lawsuits by pointing to FDA regulations it helped create (Fierce)
• CRISPR-Cas3 Platform Developer Locus Biosciences Acquires EpiBiome Phage Technology (GEN)
• Hospitals can save money on drugs without Washington’s help (STAT)
• Three years after steep price hike, Martin Shkreli’s drug company is losing money, documents show (STAT-$)
• That CRISPR study, in the cold, clear light of morning: why it’s raising concerns (STAT-$)
• Susan Collins expresses doubt on Trump proposal to post drug prices on ads (Washington Examiner)
• Could Amgen Eye Alexion as a M&A Target to Offset Neulasta Decline? (BioSpace)
• 5 drugs to watch as biotechs report Q2 (BioPharma Dive)

• Pfizer begins late-stage testing of Spark's hemophilia B gene therapy (Philadelphia Business Journal-$) (Press)
• Potential DNA damage from CRISPR has been ‘seriously underestimated,’ study finds (STAT) (The Conversation) (New Scientist) (Reuters) (Fierce)
• June was a Busy Month for the FDA, Which Approved 7 Novel Drug Approvals (BioSpace)
• Pharmacology of CAR-T Cells (News Medical)
• No more ‘sledgehammer’: As gonorrhea grows resistant to antibiotics, researchers look to bespoke treatments (STAT)
• Amyloid Plaques Better Understood through Use of High-Resolution Nanoscope (GEN)
• Llama-Derived Nanobody May Tread Narrow Anticancer Path (GEN)
• Artificial Intelligence may predict side effects of drug combinations (EPR)
• Drug derived from chilli peppers aids a loss (Deccan Chronicle)
• CytoDyn touts new data in drug-resistant HIV patients (BioPharma Dive)
• Arcus Biosciences Announces Final Safety Results From Phase 1 Trial for AB928 in Healthy Volunteers (Press)
• Viking Therapeutics Announces VK5211 Phase 2 Study Results Selected for Plenary Oral Presentation at ASBMR 2018 Annual Meeting (Press)
• Voyager Therapeutics Receives FDA Guidance on Development Path for VY-AADC for Parkinson’s Disease and Provides Clinical Update (Press)
• Asterias Provides Six Month Data Readout for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury (Press)

• Next-gen clinical decision support tools: Analytics and health data in the EHR workflow (Healthcare IT News)
• MTaI organises 'Medical Packaging Seminar’ to educate professionals on new medical device rules introduced in Europe (Pharmabiz) (Business Standard)
• Abbott’s St. Jude Medical must face negligence suit over Riata leads (MassDevice)
• BD’s Bard wins third IVC filter bellwether (MassDevice)
• Insulet settles shareholder suit over Omnipod Eros device (DDBN)
• CeQur acquires Johnson & Johnson's Calibra insulin delivery patch (MobiHealthNews)
• Medical device connectivity market could exceed $1B by 2022 (Healthcare Dive)
• Quidel Receives FDA Clearance for Solana Bordetella Complete Molecular Diagnostic Assay for the Detection of Pertussis (Whooping Cough), Parapertussis Infections (Press)

• UnitedHealth Raises Profit Outlook (WSJ)
• Next battleground for Big Tech: retail prescription drugs (Axios)
• Is Baby Powder Dangerous? Does Industry Even Care? (NYT)
• In prescription drug business, will Amazon partner with PBMs, or seek to conquer them? (STAT-$)
• Drug industry takes center stage in Senate race, as Hugin punches back against Menendez (STAT-$)
• CMS new rule: Industry reacts to big changes to telehealth, clinical documentation, and interoperability (MobiHealthNews)
• Texas' fetal remains burial law shames women, abortion providers argue in trial (Dallas News)
• Judge rules for Trump administration in suit over family-planning program shift (Reuters)
• White House: U.S. Can’t Afford Veterans’ Health Care Without Cuts (New York Magazine)

• FDA Advisory Committee Calendar

• U.K. health officials make a counteroffer to Vertex for its pricey cystic fibrosis drugs (STAT-$)
• Vertex says it's glad England made another offer for CF drugs, but it'll have to do bette (Fierce)
• Russian President calls for reform of national drugs procurement system (The Pharma Letter-$)
• Fast-growing e-cigarette maker Juul to launch in UK (Reuters)
• UK ethics body says gene-edited babies may be 'morally permissible (Reuters)
• Probiotics studies often don’t disclose safety data or risks, report finds (STAT)
• Lumendi wins CE Mark, launches DiLumen EIP in EU (MassDevice)
• Brand new x-ray technology set for production in the UK (Gov UK)
• Updated: Decide if your product is a medicine or a medical device (MHRA)
• Pause on the use of vaginally inserted surgical mesh for stress urinary incontinence. (MHRA)

• China FDA Eases Country-of-Origin Requirements for Hong Kong-based Medical Device Registrants (Emergo Group)
• Fetal Gene Therapy Prevents Fatal Form of Gaucher Disease (GEN)
• Qatar Health Ministry recalls 7 pharma products (BioSpectrum)
• Israel Govt to grant funds to GE, Change & Medtronic (BioSpectrum)
• Korean take more drugs than OECD average (Korea Biomedical Review)
• When will Seoul update drug review system for cell therapies? (Korea Biomedical Review)
• Mesoblast Enters Into Strategic Cardiovascular Alliance for China With Tasly Pharmaceutical Group (Press)

• India, Bahrain make pharma a key area of cooperation (CNBC)
• India is getting its first public healthcare record system to track the health of all citizens! (India Today)
• Biosimilar Ranibizumab Effective in Treating RVO in a Real-World Setting (The Center for Biosimilars)
• Essential list of medicines to be revised; medical devices and consumable may be included (Times of India)
• Leading 100 Indian pharma companies post dismal performance in 2017-18 with single digit growth in sales (Pharmabiz)
• Gujarat FDCA serves notices to five blood banks for dispatching unsafe blood to govt hospitals (Pharmabiz)
• LeapFrog Acquires Majority Stake in Ascent Meditech, a Leading Indian Medical Products Company (Press)

• Experimental blood test could detect melanoma skin cancer early, study finds (CNN)
• My Health Record: privacy, cybersecurity and the hacking risk (The Guardian)
• Cancer’s Grip May Be Loosened by Tampering with DNA Clamp (GEN)
• TGA business portals scheduled maintenance, 27-29 July 2018 (TGA)

• Cannabis-based drugs and devices: A winning combo? (BioPharma Dive)
• Toronto board of health to recommend decriminalization of all personal drug use (The Canadian Press) (Toronto Star)
• Former Valeant exec to take the reins at enGene (The Pharma Letter)
• Regulatory Decision Summary - Imbruvica (Health Canada)
• A first in Canada for a new technique in surgical emergencies. (Radio Canada International)

• Why Don’t More Americans Use PrEP? (NYT)
• Liver cancer death rate in US surged 43% in 16 years (CNN)
• Hospitals can save money on drugs without Washington’s help (STAT)
• Health Insurers Are Vacuuming Up Details About You — And It Could Raise Your Rates (NPR)
• Legal same-sex marriage helps gay men's health, research shows (NBC)